Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
Two recent testing guidelines were released that address carrier screenings for pregnant women and a rare disease lacking a…
From - Diagnostic Testing & Emerging Technologies
The Precision in Pediatric Sequencing (PIPseq) Program at Columbia University Medical Center released data on its first…
From - Diagnostic Testing & Emerging Technologies
A joint guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and…